| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
- Haugen, H. A., et al.
(författare)
-
CCS in the Skagerrak/Kattegat area
- 2011
-
Ingår i: Energy Procedia. 10th International Conference on Greenhouse Gas Control Technologies; Amsterdam; 19-23 September 2010. - : Elsevier BV. - 1876-6102. ; 4, s. 2324-2331
-
Konferensbidrag (refereegranskat)abstract
- This paper presents an ongoing project with the aim to assess a CO 2 infrastructure in the Skagerrak/Kattegat region (the sea bordered by north of Denmark, south coast of Norway and the west coast of Sweden). The area comprises 10-12 CO2 emission sources of more than 0.5 Mt/year. The geological and geophysical assessment of CO2 storage potential in the described area as well as reservoir modelling and simulations are performed in work package (WP) 1. The results from WP1 are used in the other work packages. Candidate storage sites are matched with those point sources in the region that are technically and economically feasible for CO2 capture, together with an assessment of the connecting infrastructure needs. WP 2 focuses on identifying optimal technological CO2 infrastructure solutions. Sources-to-sink solutions are in the process of being developed based on input from WP1 and WP3. Assessment of the build-up of a complete CCS infrastructure from a system perspective is the overall focus of WP 3, covering economical, practical and judicial aspects. The project group explores the economic potential for capture at each individual site including looking at other CO2 mitigation options and propose relevant capture technology with cost estimations. Dissemination of project results is organized in a separate work package, WP4.
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
|
|
| 16. |
|
|
| 17. |
|
|
| 18. |
|
|
| 19. |
|
|
| 20. |
- Ziegelasch, Michael, et al.
(författare)
-
Anti-cyclic citrullinated peptide antibodies are associated with radiographic damage but not disease activity in early rheumatoid arthritis diagnosed in 2006-2011
- 2020
-
Ingår i: Scandinavian Journal of Rheumatology. - : Taylor & Francis. - 0300-9742 .- 1502-7732. ; 49:6, s. 434-442
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: The discovery of anti-citrullinated protein antibodies (ACPAs) and the introduction of new therapeutic options have had profound impacts on early rheumatoid arthritis (RA) care. Since ACPA status, most widely assessed as reactivity to cyclic citrullinated peptides (CCPs), influences treatment decisions in early RA, we aimed to determine whether anti-CCP remains a predictor of disease activity and radiographic joint damage in more recent 'real-world' early RA.Method: Two observational early RA cohorts from Sweden enrolled patients in 1996-1999 (TIRA-1, n = 239) and 2006-2009 (TIRA-2, n = 444). Clinical and radiographic data and ongoing treatment were prospectively collected up to 3 years. Two other cohorts served as confirmation cohorts (TRAM-1, with enrolment 1996-2000, n = 249; and TRAM-2, 2006-2011, n = 528). Baseline anti-CCP status was related to disease activity, pharmacotherapy, and radiographic joint damage according to Larsen score.Results: In the TIRA-1 cohort, anti-CCP-positive patients had significantly higher 28-joint Disease Activity Score, swollen joint count, C-reactive protein level, and erythrocyte sedimentation rate during follow-up compared with anti-CCP-negative patients. In TIRA-2, no such differences were found, but baseline anti-CCP positivity was associated with higher 3 year Larsen score (5.4 vs 3.5, p = 0.039). In TRAM-2, anti-CCP also predicted radiographic damage (8.9 vs 6.7, p = 0.027), with no significant differences in disease activity.Conclusion: In the early RA cohorts recruiting patients in 2006-2011, baseline anti-CCP positivity was not associated with disease activity over time, but was associated with increased radiographic damage at follow-up. Hence, close radiographic monitoring is warranted in early anti-CCP-positive RA regardless of disease activity.
|
|
